Jon has been reporting on stock markets for over twenty-five years for audio text companies (remember them?!), newswires, and websites. He helped set up MarketEye News for ICV/Topic in the 1990’s before moving on to become a Markets reporter at AFX News. After over 10 years, which saw him rise to the dizzy heights of Markets Editor at AFX, the firm’s acquisition by Thomson Corp and subsequent takeover of Reuters, he moved on in 2012. Prior to Proactive Investors, he was News Editor for thisismoney.co.uk, the Mail Online’s financial website.
The FTSE 100-listed firm said its adjusted earnings per share rose by 31% to 25.0p in the quarter to March 31, beating forecasts for 24.5p
Stephen O’Hara created Opti as a company all by himself in 2012 as a business focused on the rapidly growing microbiome space, which harnesses the positive benefits of microbes that live on the human body
In separate statements, both companies said there was no certainty the discussions would lead to a deal
Jazz will grant Hikma and its wholly-owned subsidiary West-Ward Pharmaceuticals Corp the right to sell an authorised generic version of Xyrem in the US from the beginning of January 2023
Circassia booked restructuring costs and impairments of £80.0mln in 2016 leading it to report a pretax loss of £144.9mln, up from a £62.8mln loss in 2015
Louise Makin, BTG’s CEO, said: "Our business has performed well this year. We have made significant progress in executing our strategy to become a leading provider of Interventional Medicine therapies.”
The data, expected in the next month or so, will keep the biotech firm on track to take the first Affimer candidate into phase 1 studies, targeted for 2019
The Euronext-listed late clinical-stage company reported revenue of €517,738 for the three months to December 31, up from €58,556 in the third quarter.